Treatment for semantic variant frontotemporal dementia
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This study tests an investigational treatment for people with a specific type of frontotemporal dementia called semantic variant. It aims to see if the treatment is safe and can slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of frontotemporal dementia, specifically the semantic variant.
- Your dementia should be mild to moderate in severity.
- Tests must show you do not have Alzheimer's disease proteins (amyloid) in your brain.
- You must not have other brain diseases or uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called AVB-101 for people with a specific genetic cause of frontotemporal dementia (FTD). The therapy is given as a one-time injection into the brain to potentially slow or stop the disease.
This study looks at testing (including brain scans) to figure out what type of frontotemporal dementia or related language/speech condition a person has. It may help by making diagnoses more accurate, which can guide better care.
This trial tests a new treatment using tiny particles from stem cells (exosomes) given through an IV. It aims to slow down or improve symptoms of frontotemporal dementia, a type of dementia that affects behavior and language.
This study uses special MRI and PET scans to compare the brains of people with Alzheimer's disease, frontotemporal dementia, and healthy individuals. The goal is to better understand how these conditions affect the brain, which may help doctors tell them apart more clearly.
This trial tests if vortioxetine, an antidepressant, can improve mood symptoms (like depression or anxiety) and thinking abilities in people with frontotemporal dementia (FTD). It also includes healthy volunteers for comparison.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Hear when a new Dementia Frontotemporal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.